There are 2789 resources available
1302P - Immune signatures of second-line PD-1 immune checkpoint blockade
Presenter: Kenneth O'Byrne
Session: ePoster Display
1303P - A clinical variable based nomogram could predict survival for NSCLC patients receiving atezolizumab
Presenter: Xiaoling Shang
Session: ePoster Display
1304P - Interleukin-6 (IL-6) as a potential predictive marker and a desensitizer for immunotherapy response in non-small cell lung cancer
Presenter: Yan Wang
Session: ePoster Display
1305P - Peripheral low-density neutrophils in the response to immunotherapy in untreated non-small cell lung cancer
Presenter: Hugo Arasanz
Session: ePoster Display
1306P - Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Presenter: Atsushi Nakamura
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display
1309P - A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)
Presenter: Martin Reck
Session: ePoster Display
1310P - Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
Presenter: man Jiang
Session: ePoster Display
1311P - The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
Presenter: Emma Zattarin
Session: ePoster Display